Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2017

Pharma News, 2017

Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
SANTA MONICA, Calif.
Juno ends development of high-profile leukemia drug after deaths
Juno ends development of high-profile leukemia drug after deaths
Juno Therapeutics Inc on Wednesday said it decided to shut down development of an experimental leukemia treatment from a highly promising new class of immunotherapy following an investigation into tox...
Accera's Alzheimer's trial fails, in yet another setback for disease
Accera's Alzheimer's trial fails, in yet another setback for disease
Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for ...
FDA approves Perrigo’s hydrocodone bitartrate and homatropine methylbromide
FDA approves Perrigo’s hydrocodone bitartrate and homatropine methylbromide
WASHINGTON — The U.
FDA Approves Qtern
FDA Approves Qtern
28 February 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment ...
FDA approves Xermelo for carcinoid syndrome diarrhea
FDA approves Xermelo for carcinoid syndrome diarrhea
The U.
Stada recieves a $3.7 billion offer
Stada recieves a $3.7 billion offer
German company announced that Boston private equity outfit Advent International had put up a legally binding bid of €58 per share in cash, plus a 2016 dividend payment; in 2015, that payment amounte...
Merck drug prevents serious infection after marrow transplant: study
Merck drug prevents serious infection after marrow transplant: study
An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with p...
Six new medicines endorsed for EU approval
Six new medicines endorsed for EU approval
Six new medicines, including the first hormone replacement therapy for a thyroid disorder, have been put forward for approval by the European Medicines Agency's Committee for Medicinal Products fo...
Health care leaders gather in Washington
Health care leaders gather in Washington
WASHINGTON — Leaders across the health care continuum on Thursday gathered in Washington, D.
Sanofi and Lonza will build new $285 million biologics facility
Sanofi and Lonza will build new $285 million biologics facility
French drugmaker Sanofi and Swiss manufacturer Lonza will invest 270 million euros ($285 million) in a new large-scale biologics facility that will produce monoclonal antibodies by 2020.
Shares hit by Bayer results but pharma growth continues
Shares hit by Bayer results but pharma growth continues
A fourth-quarter 2016 dip in income hit the 2016 financial results of Germany’s Bayer (BAYN.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand